ES2097717T1 - Adn que codifica un receptor (y4) humano neuropeptido y/peptido yy/polipeptido pancreatico y usos del mismo. - Google Patents

Adn que codifica un receptor (y4) humano neuropeptido y/peptido yy/polipeptido pancreatico y usos del mismo.

Info

Publication number
ES2097717T1
ES2097717T1 ES95907215T ES95907215T ES2097717T1 ES 2097717 T1 ES2097717 T1 ES 2097717T1 ES 95907215 T ES95907215 T ES 95907215T ES 95907215 T ES95907215 T ES 95907215T ES 2097717 T1 ES2097717 T1 ES 2097717T1
Authority
ES
Spain
Prior art keywords
human
receptor
nucleic acid
acid molecule
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95907215T
Other languages
English (en)
Other versions
ES2097717T3 (es
ES2097717T5 (es
Inventor
Jonathan A Bard
Mary W Walker
Theresa Branchek
Richard L Weinshank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Research USA Inc
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22644257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097717(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Publication of ES2097717T1 publication Critical patent/ES2097717T1/es
Publication of ES2097717T3 publication Critical patent/ES2097717T3/es
Application granted granted Critical
Publication of ES2097717T5 publication Critical patent/ES2097717T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

ESTA INVENCION INCLUYE UNA MOLECULA DE ACIDO NUCLEICO AISLADA QUE CODIFICA UN RECEPTOR Y4 HUMANO, UNA PROTEINA AISLADA QUE ES UN RECEPTOR Y4 HUMANO, LOS VECTORES QUE INCLUYEN LA MOLECULA DE ACIDO NUCLEICO AISLADA QUE CODIFICA EL RECEPTOR Y4 HUMANO, LAS CELULAS DE MAMIFERO QUE CONTIENEN DICHOS VECTORES, LOS ANTICUERPOS CONTRA EL RECEPTOR Y4 HUMANO, LAS SONDAS DE ACIDOS NUCLEICOS UTILES PARA DETECTAR LOS ACIDOS NUCLEICOS QUE CODIFICAN A LOS RECEPTORES Y4 HUMANOS, LOS OLIGONUCLEOTIDOS ANTISENTIDO COMPLEMENTARIOS A TODAS LAS SECUENCIAS DE UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA A UN RECEPTOR Y4 HUMANO, LOS COMPUESTOS FARMACEUTICOS RELACIONADOS CON LOS RECEPTORES Y4 HUMANOS Y LOS ANIMALES TRANSGENICOS NO HUMANOS QUE EXPRESAN EL ADN QUE CODIFICA UN RECEPTOR Y4 HUMANO NORMAL O MUTANTE. ESTA INVENCION INCLUYE, ADEMAS, LOS METODOS PARA DETERMINAR LA UNION DEL LIGANDO, DETECTAR LA EXPRESION, INVESTIGAR LOS MEDICAMENTOS Y LOS METODOS DE TRATAMIENTO RELACIONADOS CON EL RECEPTOR Y4 HUMANO.
ES95907215T 1993-12-28 1994-12-28 Dna codificante de un receptor de neuropeptido y/peptido yy/polipeptido pancreatico humano (y4) y sus aplicaciones. Expired - Lifetime ES2097717T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US176412 1993-12-28
US08/176,412 US5516653A (en) 1993-12-28 1993-12-28 DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof

Publications (3)

Publication Number Publication Date
ES2097717T1 true ES2097717T1 (es) 1997-04-16
ES2097717T3 ES2097717T3 (es) 2000-06-16
ES2097717T5 ES2097717T5 (es) 2010-10-18

Family

ID=22644257

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907215T Expired - Lifetime ES2097717T5 (es) 1993-12-28 1994-12-28 Dna codificante de un receptor de neuropeptido y/peptido yy/polipeptido pancreatico humano (y4) y sus aplicaciones.

Country Status (11)

Country Link
US (4) US5516653A (es)
EP (1) EP0746332B2 (es)
JP (1) JP4216326B2 (es)
AT (1) ATE189607T1 (es)
AU (1) AU702438B2 (es)
CA (1) CA2156272C (es)
DE (2) DE69423007T3 (es)
DK (1) DK0746332T4 (es)
ES (1) ES2097717T5 (es)
GR (1) GR970300026T1 (es)
WO (1) WO1995017906A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
JPH10508486A (ja) * 1994-11-07 1998-08-25 メルク エンド カンパニー インコーポレーテッド 修飾神経ペプチドｙレセプター
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) * 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5916869A (en) * 1997-06-13 1999-06-29 North Carolina State University Method of treating birds in ovo
GB2344050A (en) * 1998-11-26 2000-05-31 Ferring Bv Agents useful in the treatment of reproductive disorders.
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
AU6727900A (en) * 1999-08-27 2001-03-26 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001053477A1 (en) * 2000-01-20 2001-07-26 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of neuropeptide y activity
ATE386821T1 (de) 2000-10-23 2008-03-15 Gen Probe Inc Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2)
EP1403380A1 (en) * 2002-09-27 2004-03-31 Integragen Human obesity susceptibility gene and uses thereof
ES2314206T3 (es) * 2002-05-15 2009-03-16 Integragen Gen humano de predisposicion a la obesidad y usos del mismo.
EP1362926A1 (en) * 2002-05-15 2003-11-19 Integragen Human obesity susceptibility gene and uses thereof
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
WO2004087882A2 (en) * 2003-03-26 2004-10-14 Washington University Neuregulin protein regulation of synaptic proteins
US20070083037A1 (en) * 2003-10-30 2007-04-12 Hideki Sano Monkey npy y4 receptor and method of evaluating compound
US20070270339A1 (en) * 2004-04-23 2007-11-22 Serono, Inc. Use of GPCR54 Ligands for the Treatment of Infertility
AU2005249504A1 (en) * 2004-05-28 2005-12-15 Laboratoires Serono Sa Use of IL-17 in the treatment of fertility-related disorders
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006091506A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y4 receptor agonists
AU2005337116A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
ATE516301T1 (de) 2005-09-21 2011-07-15 7Tm Pharma As Y2-selektive rezeptoragonisten für therapeutische eingriffe
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
US20090029406A1 (en) 2006-02-24 2009-01-29 Banyu Pharmaceutical Co., Ltd. Npy Y4 Agonist as Therapeutic Agent for Disease Accompanied by Intestinal Tract Dysfunction
MX2011008775A (es) * 2009-02-20 2011-10-24 Ipsen Pharma Sas Analogos de neuropeptidos y con substitucion de prolina en la posicion 34.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US5026685A (en) * 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5328899A (en) * 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
GB8818020D0 (en) * 1988-07-28 1988-09-01 Ici Plc Method for amplification of nucleotide sequences
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists
ZA896374B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y antagonists
US5053337A (en) * 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
ES2058651T3 (es) * 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
JPH0463594A (ja) * 1990-07-03 1992-02-28 Tanpaku Kogaku Kenkyusho:Kk 成長ホルモンレセプターのホルモン結合領域蛋白の製造法
ATE180510T1 (de) * 1991-11-06 1999-06-15 Garvan Inst Med Res Humaner neuropeptid y-y1 rezeptor
WO1993024515A1 (en) * 1992-05-29 1993-12-09 Cornell Research Foundation, Inc. Human neuropeptide y/peptide yy receptor of the y1-type and antisense oligonucleotides thereto which inhibit vasoconstriction
GB9213215D0 (en) * 1992-06-20 1992-08-05 Wellcome Found Peptides
JPH06116284A (ja) * 1992-10-02 1994-04-26 Yamanouchi Pharmaceut Co Ltd 新規ペプチド
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
SK121895A3 (en) * 1993-03-29 1996-10-02 Univ Cincinnati Analogues of peptide yy and uses thereof
WO1995000161A1 (en) * 1993-06-18 1995-01-05 University Of Cincinnati Neuropeptide y antagonists and agonists
US5516653A (en) 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
CA2134428A1 (en) * 1994-10-26 1996-04-27 Albert Tseng Neuropeptide y y2 agonist peptides
JPH10508486A (ja) * 1994-11-07 1998-08-25 メルク エンド カンパニー インコーポレーテッド 修飾神経ペプチドｙレセプター
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5621079A (en) * 1995-02-03 1997-04-15 Merck & Co., Inc. Neuropeptide Y receptor
AUPN646795A0 (en) * 1995-11-09 1995-11-30 Garvan Institute Of Medical Research Neuropeptide Y-Y5 receptor
US5965392A (en) * 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6355478B1 (en) * 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor

Also Published As

Publication number Publication date
GR970300026T1 (en) 1997-09-30
DE69423007T3 (de) 2011-02-10
CA2156272A1 (en) 1995-07-06
EP0746332A1 (en) 1996-12-11
WO1995017906A1 (en) 1995-07-06
ES2097717T3 (es) 2000-06-16
DE746332T1 (de) 1997-04-10
EP0746332A4 (en) 1997-02-26
DK0746332T3 (da) 2000-06-13
US5516653A (en) 1996-05-14
US5976814A (en) 1999-11-02
EP0746332B2 (en) 2010-05-19
AU1551895A (en) 1995-07-17
DE69423007T2 (de) 2000-10-19
EP0746332B1 (en) 2000-02-09
US6913892B1 (en) 2005-07-05
DE69423007D1 (de) 2000-03-16
CA2156272C (en) 2009-09-15
JP4216326B2 (ja) 2009-01-28
US5958709A (en) 1999-09-28
JPH09511127A (ja) 1997-11-11
ES2097717T5 (es) 2010-10-18
ATE189607T1 (de) 2000-02-15
AU702438B2 (en) 1999-02-18
DK0746332T4 (da) 2010-08-16

Similar Documents

Publication Publication Date Title
ES2097717T1 (es) Adn que codifica un receptor (y4) humano neuropeptido y/peptido yy/polipeptido pancreatico y usos del mismo.
ES2083344T1 (es) Dna que codifica un receptor 5-ht1f humano y utilizacion del mismo.
DK0530265T3 (da) DNA kodende for humane 5-HT1D-receptorer og anvendelser deraf
WO1994014957A3 (en) Dna encoding 5-ht4 serotonin receptors and uses thereof
NO20020861D0 (no) PD-1, en reseptor for B7-4, og anvendelser derav
GR960300015T1 (es)
EP1075493A4 (en) DNA ENCODING THE SNORF25 RECEPTOR
GR950300067T1 (en) Dna encoding human alpha 1 adrenergic receptors and uses thereof.
EP0538395A4 (en) Nucleic acid sequences encoding a human dopamine d 1? receptor
CA2127117A1 (en) DNA Encoding a Human Serotonin Receptor (5-HT4B) and Uses Thereof
DE69417223D1 (de) Ein menschlicher t-zell rezeptor der protein g-gekoppelte rezeptor familie
EP1412374A4 (en) NEW PGC-1 ISOFORMS AND THEIR USES
MXPA02000293A (es) Isoformas de la amp ciclico fosfodiesterasa y metodos de uso.
WO2001000673A8 (en) Membrane-associated and secreted proteins and uses thereof
Gerald et al. DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
DE69120380D1 (de) TXA2-Rezeptor und dafür kodierendes Gen
Weinshank et al. DNA encoding a human 5-HT1F receptor, vectors, and host cells
WO2000050442A3 (en) Secreted proteins and uses thereof

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746332

Country of ref document: ES